Tessa Therapeutics Pte Ltd. logo

Tessa Therapeutics Pte Ltd.

A biotechnology company focused on the development and commercialization of immunotherapies. We are a leader in employing Virus-Specific Tcells to treat cancer. Tessa Therapeutics is a clinical stage biopharmaceutical company developing treatment of cancer by redirecting the bodys potent anti-viral immune response to recognize and kill cancer cells.

The National Cancer Centre Singapore, is a strategic shareholder of Tessa and has granted exclusive rights to immuno-oncology technologies to Tessa. The company has exclusive licenses to multiple technologies developed at Baylor College of Medicine.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.tessatherapeutics.com
Founded2011
Disease Focus
Development Stage
STOCK CODENon Listed
Address
8 Temasek Boulevard, #24-02 Suntec Tower 3, 38988
Singapore
Email
Contact Number
+65 6384 0755

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/tessa-therapeutics” connections=”true” suffix=””]

Tessas core virus-specific T cell (VST) platform employ bodys anti-viral immune response to rationally design the next generation of cancer treatments. After infusion, the VSTs migrate to the tumor site and bind to the viral antigens located on the surface of the tumor.. The act of binding causes the release of cytotoxic granules from the VSTs that destroy the cancer cells.

In Apr 2017, Tessa Therapeutics signed a collaboration with Vyriad Inc. to investigate Tessas HPV-specific T cells with Vyriads vesicular stomatitis virus (VSV) for the treatment of HPV-associated cancers such as cervical as well as head and neck cancers.The financial details remains undisclosed.

In April 2018, Tessa Therapeutics closed $130 Mn Series C in two rounds, led by Temasek, an investment company headquartered in Singapore, and joined by EDBI, Karst Peak Capital, Heliconia, Heritas and other investors.